Clinical Scorecard: This Week's CGT News: World's First Solid Tumor CAR T Approved in China
At a Glance
Category
Detail
Condition
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Key Mechanisms
Autologous CAR T-cell therapy targeting Claudin18.2
Target Population
Patients with Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma who have failed at least two prior lines of therapy
Care Setting
Oncology
Key Highlights
First CAR T-cell therapy approved for a solid tumor in China
Satricabtagene autoleucel (satri-cel) shows progression-free and overall survival benefits
Median progression-free survival of 3.25 months with satri-cel versus 1.77 months with physician's choice
Median overall survival of 7.92 months with satri-cel versus 5.49 months with physician's choice
Approval supported by randomized phase 2 CT041-ST-01 trial
Guideline-Based Recommendations
Diagnosis
Identify Claudin18.2-positive tumors in patients with advanced gastric or gastroesophageal junction adenocarcinoma
Management
Consider satricabtagene autoleucel for patients who have failed at least two prior lines of therapy
Monitoring & Follow-up
Monitor for progression-free survival and overall survival outcomes post-treatment
Risks
Potential for cytokine release syndrome and other CAR T-cell therapy-related toxicities
Patient & Prescribing Data
Patients with advanced gastric or gastroesophageal junction adenocarcinoma
Satricabtagene autoleucel provides a new treatment option for patients with limited alternatives
Clinical Best Practices
Utilize biomarkers for patient selection in CAR T-cell therapy
Implement monitoring strategies for early detection of adverse effects
